INSM
VENTE TOTALE: 42 797 titres (~4 566 973,77 $ US)
- Insiders
- Lewis William
- Total bought
- —
- Total sold
- $4,566,974
- Last activity
- 2026-07-23
- Last synced
-
2026-07-29 15:28:58
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
INSM presents a mixed profile: a moderate earnings catalyst (positive ESP, bullish analyst initiation ahead of Q2 2026) is partially offset by deeply deteriorating fundamentals, extreme negative margins, and a…
The first sentence of the analysis written for INSM on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.4% | 76.4% | 78.5% | 77.5% | 76.6% | |
| Ebit Margin | -195.9% | -228.2% | -219.8% | -186.5% | -211.1% | |
| Ebitda Margin | -193.2% | -225.1% | -216.3% | -182.3% | -203.6% | |
| Operating Profit Margin | -194.0% | -241.5% | -232.5% | -186.4% | -199.0% | |
| Pretax Profit Margin | -209.7% | -250.2% | -244.8% | -195.7% | -231.6% | |
| Continuous Operations Profit Margin | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | |
| Net Profit Margin | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | |
| Bottom Line Profit Margin | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | |
| Current Ratio | 3.827 | 5.450 | 4.118 | 6.693 | 6.193 | |
| Quick Ratio | 3.545 | 5.119 | 3.749 | 6.326 | 5.697 | |
| Solvency Ratio | -0.826 | -0.519 | -0.445 | -0.300 | -0.505 | |
| Cash Ratio | 1.089 | 1.865 | 2.138 | 5.646 | 5.303 | |
| Price To Earnings Ratio | -27.151 | -12.395 | -5.803 | -5.110 | -7.021 | |
| Price To Earnings Growth Ratio | -1.800 | -2.878 | -0.159 | -6.609 | -0.243 | |
| Forward Price To Earnings Growth Ratio | -1.800 | -2.878 | -0.159 | -6.609 | -0.243 | |
| Price To Book Ratio | 50.315 | 39.686 | -13.112 | 27.950 | 7.440 | |
| Price To Sales Ratio | 61.313 | 31.139 | 14.259 | 10.019 | 16.204 | |
| Price To Free Cash Flow Ratio | -38.427 | -16.046 | -7.919 | -5.991 | -8.241 | |
| Price To Operating Cash Flow Ratio | -39.766 | -16.561 | -8.116 | -6.139 | -8.406 | |
| Debt To Assets Ratio | 0.339 | 0.649 | 0.905 | 0.711 | 0.492 | |
| Debt To Equity Ratio | 1.039 | 4.605 | -3.627 | 13.392 | 1.492 | |
| Debt To Capital Ratio | 0.510 | 0.822 | 1.381 | 0.931 | 0.599 | |
| Long Term Debt To Capital Ratio | 0.492 | 0.816 | 1.403 | 0.928 | 0.580 | |
| Financial Leverage Ratio | 3.064 | 7.097 | -4.006 | 18.834 | 3.029 | |
| Working Capital Turnover Ratio | 0.458 | 0.359 | 0.342 | 0.275 | 0.313 | |
| Operating Cash Flow Ratio | -1.994 | -2.299 | -2.377 | -2.105 | -2.688 | |
| Operating Cash Flow Sales Ratio | -1.542 | -1.880 | -1.757 | -1.632 | -1.928 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | 1.032 | 1.025 | 1.025 | 1.020 | |
| Debt Service Coverage Ratio | -11.416 | -8.111 | -8.112 | -16.968 | -9.436 | |
| Interest Coverage Ratio | -14.043 | -10.343 | -8.686 | -17.293 | -9.268 | |
| Short Term Operating Cash Flow Coverage Ratio | -48.539 | -41.457 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.217 | -0.520 | -0.445 | -0.340 | -0.593 | |
| Capital Expenditure Coverage Ratio | -28.716 | -31.195 | -40.356 | -40.538 | -49.843 | |
| Dividend Paid And Capex Coverage Ratio | -28.716 | -31.195 | -40.356 | -40.538 | -49.843 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -31.958 | -14.759 | -7.685 | -5.727 | -7.688 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.4% | ▲3.0% | ▲1.7% |
| Ebit Margin | -195.9% | ▲32.3% | ▲12.4% |
| Ebitda Margin | -193.2% | ▲31.9% | ▲10.9% |
| Operating Profit Margin | -194.0% | ▲47.4% | ▲16.6% |
| Pretax Profit Margin | -209.7% | ▲40.5% | ▲16.7% |
| Continuous Operations Profit Margin | -210.5% | ▲40.7% | ▲16.3% |
| Net Profit Margin | -210.5% | ▲40.7% | ▲16.3% |
| Bottom Line Profit Margin | -210.5% | ▲40.7% | ▲16.3% |
| Current Ratio | 3.827 | ▼-1.624 | ▼-1.429 |
| Quick Ratio | 3.545 | ▼-1.574 | ▼-1.342 |
| Solvency Ratio | -0.826 | ▼-0.307 | ▼-0.307 |
| Cash Ratio | 1.089 | ▼-0.777 | ▼-2.119 |
| Price To Earnings Ratio | -27.151 | ▼-14.756 | ▼-15.655 |
| Price To Earnings Growth Ratio | -1.800 | ▲1.077 | ▲0.537 |
| Forward Price To Earnings Growth Ratio | -1.800 | ▲1.077 | ▲0.537 |
| Price To Book Ratio | 50.315 | ▲10.629 | ▲27.859 |
| Price To Sales Ratio | 61.313 | ▲30.174 | ▲34.726 |
| Price To Free Cash Flow Ratio | -38.427 | ▼-22.381 | ▼-23.102 |
| Price To Operating Cash Flow Ratio | -39.766 | ▼-23.205 | ▼-23.968 |
| Debt To Assets Ratio | 0.339 | ▼-0.310 | ▼-0.280 |
| Debt To Equity Ratio | 1.040 | ▼-3.565 | ▼-2.341 |
| Debt To Capital Ratio | 0.510 | ▼-0.312 | ▼-0.339 |
| Long Term Debt To Capital Ratio | 0.492 | ▼-0.324 | ▼-0.352 |
| Financial Leverage Ratio | 3.064 | ▼-4.032 | ▼-2.539 |
| Working Capital Turnover Ratio | 0.458 | ▲0.099 | ▲0.109 |
| Operating Cash Flow Ratio | -1.994 | ▲0.304 | ▲0.298 |
| Operating Cash Flow Sales Ratio | -1.542 | ▲0.339 | ▲0.206 |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | ▲0.003 | ▲0.007 |
| Debt Service Coverage Ratio | -11.416 | ▼-3.305 | ▼-0.608 |
| Interest Coverage Ratio | -14.043 | ▼-3.700 | ▼-2.116 |
| Short Term Operating Cash Flow Coverage Ratio | -48.539 | ▼-7.082 | ▼-30.540 |
| Operating Cash Flow Coverage Ratio | -1.217 | ▼-0.697 | ▼-0.594 |
| Capital Expenditure Coverage Ratio | -28.716 | ▲2.479 | ▲9.414 |
| Dividend Paid And Capex Coverage Ratio | -28.716 | ▲2.479 | ▲9.414 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -31.958 | ▼-17.199 | ▼-18.395 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $37.18B | $11.33B | $4.35B | $2.46B | $3.05B | |
| Enterprise value | $37.44B | $12.08B | $5.07B | $2.56B | $2.95B | |
| EV / Sales | 61.74x | 33.23x | 16.62x | 10.44x | 15.65x | |
| EV / Op. cash flow | -40.04x | -17.67x | -9.46x | -6.40x | -8.12x | |
| EV / Free cash flow | -38.69x | -17.12x | -9.23x | -6.24x | -7.96x | |
| EV / EBITDA | -31.96x | -14.76x | -7.68x | -5.73x | -7.69x | |
| Net debt / EBITDA | -0.22x | -0.93x | -1.09x | -0.23x | 0.27x | |
| Current ratio | 3.83x | 5.45x | 4.12x | 6.69x | 6.19x | |
| Income quality | 0.73x | 0.75x | 0.71x | 0.83x | 0.84x | |
| Graham net-net | $0 | -$1 | -$6 | -$3 | -$1 | |
| Tax burden | 100.4% | 100.4% | 100.3% | 100.3% | 99.6% | |
| Interest burden | 107.1% | 109.7% | 111.4% | 104.9% | 109.7% | |
| Working capital | $1.33B | $1.32B | $703.4M | $1.08B | $701.9M | |
| Invested capital | $1.70B | $1.63B | $1.01B | $1.39B | $1.01B | |
| Return on assets | -56.4% | -45.1% | -56.4% | -29.1% | -35.0% | |
| Operating ROA | -54.9% | -52.4% | -47.5% | -31.5% | -36.8% | |
| Return on tangible assets | -62.9% | -49.9% | -66.3% | -33.2% | -42.1% | |
| Return on equity | -172.8% | -320.2% | 225.8% | -547.5% | -105.9% | |
| Return on invested capital | -64.8% | -50.4% | -63.7% | -31.0% | -33.4% | |
| Return on capital employed | -65.5% | -50.8% | -64.3% | -31.2% | -33.8% | |
| Earnings yield | -3.4% | -8.1% | -17.2% | -19.6% | -14.2% | |
| Free cash flow yield | -2.6% | -6.2% | -12.6% | -16.7% | -12.1% | |
| Capex / Op. cash flow | -3.5% | -3.2% | -2.5% | -2.5% | -2.0% | |
| Capex / Depreciation | 197.9% | 199.1% | 125.6% | 95.6% | 51.4% | |
| Capex / Sales | 5.4% | 6.0% | 4.4% | 4.0% | 3.9% | |
| SG&A / Sales | 115.6% | 126.8% | 112.9% | 108.3% | 124.3% | |
| R&D / Sales | 127.2% | 164.5% | 187.1% | 162.0% | 144.7% | |
| Stock comp / Sales | 25.2% | 26.6% | 24.5% | 23.5% | 24.4% | |
| Intangibles / Total assets | 10.3% | 9.6% | 15.0% | 12.4% | 16.9% | |
| Days sales outstanding | 85d | 52d | 49d | 44d | 47d | |
| Days payables outstanding | 234d | 311d | 364d | 334d | 296d | |
| Operating cycle | 471d | 472d | 513d | 507d | 601d | |
| Cash conversion cycle | 237d | 161d | 149d | 173d | 305d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+228.3%EV / Sales ▲+85.8%EV / EBITDA ▼-116.5%EV / Op. cash flow ▼-22.371Earnings yield ▲+0.046
Profitability
Return on equity ▲+1.474Return on assets ▼-0.113Return on invested capital ▼-0.145Return on capital employed ▼-0.147Operating ROA ▼-0.025Income quality ▼-0.016Tax burden -0.000
Efficiency
Days sales outstanding ▲+32.584Days payables outstanding ▼-77.336Operating cycle ▼-1.034Cash conversion cycle ▲+76.302Capex / Sales ▼-0.007R&D / Sales ▼-0.374
Balance-sheet strength
Current ratio ▼-1.624Net debt / EBITDA ▲+0.707Working capital ▲+1201000.000Invested capital ▲+63829000.000Intangibles / Total assets ▲+0.007
Change over 5 years
Valuation
Market cap ▲+1117.5%EV / Sales ▲+294.5%EV / EBITDA ▼-315.7%EV / Op. cash flow ▼-31.923Earnings yield ▲+0.108
Profitability
Return on equity ▼-0.669Return on assets ▼-0.214Return on invested capital ▼-0.314Return on capital employed ▼-0.317Operating ROA ▼-0.181Income quality ▼-0.104Tax burden ▲+0.008
Efficiency
Days sales outstanding ▲+37.619Days payables outstanding ▼-62.261Operating cycle ▼-130.313Cash conversion cycle ▼-68.052Capex / Sales ▲+0.015R&D / Sales ▼-0.176
Balance-sheet strength
Current ratio ▼-2.366Net debt / EBITDA ▼-0.492Working capital ▲+623460000.000Invested capital ▲+690997000.000Intangibles / Total assets ▼-0.066
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-06-10 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2025-10-03 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-09-22 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-08 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-07 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-06-16 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-04-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-21 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2024-05-28 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2022-12-06 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-07-27 Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss? Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
- 2026-07-23 Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.
- 2026-07-22 Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSM Andra AP fonden lifted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 114.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,970 shares of the biopharmaceutical company's stock after acquiring an additional 41,670 shares during the
- 2026-07-21 This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- 2026-07-21 Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.
- 2026-07-20 Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today? Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biotech names on wildly different trajectories, the one semiconductor stock nobody can ignore, and an Argentine oil producer sitting on a shale reserve about to unlock its first export pipeline.
- 2026-07-19 Bank of New York Mellon Corp Cuts Stake in Insmed, Inc. $INSM Bank of New York Mellon Corp lessened its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 9.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,262,749 shares of the biopharmaceutical company's stock after selling 127,293 shares
- 2026-07-16 Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript
- 2026-07-16 Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning Insmed Incorporated (NASDAQ:INSM) on Thursday reported 12-month results from the ongoing open-label extension (OLE) study of its once-daily treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) patients.
- 2026-07-16 Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study Insmed NASDAQ: INSM reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension, saying the data showed sustained efficacy measures and a generally favorable safety profile over longer-term use.